Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648620 · ClinicalTrials.gov registry record · NA
Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon
A NA study, sponsored by SurModics.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT02648620: Completed NA study, sponsored by SurModics.
NCT02648620 is a NA study that has completed, run by SurModics. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02648620, a NA study, has completed, sponsored by SurModics.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
PREVEIL is a prospective, multi-center, single-arm clinical trial to assess the safety and functionality of the SurModics drug coated balloon (DCB) in the treatment of subjects with symptomatic peripheral artery disease (PAD) due to de novo stenoses of the femoral and popliteal arteries. The trial will enroll up to 15 subjects.
Primary Outcome
Paclitaxel plasma levels will be assessed at baseline, immediately post-index procedure, at 1h, 2h, 4h, 12h (or upon discharge), and 30 days post-index procedure.
Interventions
- PROCEDURE Angioplasty
- DEVICE SurVeil Drug Coated Balloon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-04-05 |
| Est. Completion | 2020-02-11 |
| Phase | NA |
What the finished NCT02648620 record still lists
NCT02648620 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Angioplasty is the first listed.
NCT02648620 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02648620 about?
NCT02648620 is a clinical study titled "Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon". PREVEIL is a prospective, multi-center, single-arm clinical trial to assess the safety and functionality of the SurModics drug coated balloon (DCB) in the treatment of subjects with symptomatic peripheral artery disease (PAD) due to de novo stenoses of the femoral and popliteal arteries. The trial w...
What is the current status of trial NCT02648620?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2016-04-05. Estimated completion is 2020-02-11.
What interventions are being tested in trial NCT02648620?
The interventions under investigation include: Angioplasty (PROCEDURE), SurVeil Drug Coated Balloon (DEVICE).
Who is sponsoring clinical trial NCT02648620?
This trial is sponsored by SurModics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02648620's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI